Pasithea Therapeutics (KTTA) Accumulated Depreciation (2022 - 2024)
Pasithea Therapeutics (KTTA) has disclosed Accumulated Depreciation for 3 consecutive years, with $37636.0 as the latest value for Q3 2024.
- Quarterly Accumulated Depreciation changed N/A to $37636.0 in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $37636.0 through Sep 2024, changed N/A year-over-year, with the annual reading at $23488.0 for FY2023, 559.96% up from the prior year.
- Accumulated Depreciation hit $37636.0 in Q3 2024 for Pasithea Therapeutics, up from $32920.0 in the prior quarter.
- In the past five years, Accumulated Depreciation ranged from a high of $37636.0 in Q3 2024 to a low of $3559.0 in Q4 2022.
- Historically, Accumulated Depreciation has averaged $25161.6 across 3 years, with a median of $28205.0 in 2024.
- Biggest YoY gain for Accumulated Depreciation was 559.96% in 2023; the steepest drop was 559.96% in 2023.
- Year by year, Accumulated Depreciation stood at $3559.0 in 2022, then soared by 559.96% to $23488.0 in 2023, then skyrocketed by 60.24% to $37636.0 in 2024.
- Business Quant data shows Accumulated Depreciation for KTTA at $37636.0 in Q3 2024, $32920.0 in Q2 2024, and $28205.0 in Q1 2024.